{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T18:24:04Z","timestamp":1787682244824,"version":"build-2784847793"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004901","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de Minas Gerais","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004901","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004901","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de Minas Gerais","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004901","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","jns-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.jns.2017.08.3250","type":"journal-article","created":{"date-parts":[[2017,8,25]],"date-time":"2017-08-25T00:01:33Z","timestamp":1503619293000},"page":"169-175","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Body composition and adipokines plasma levels in patients with myasthenia gravis treated with high cumulative glucocorticoid dose"],"prefix":"10.1016","volume":"381","author":[{"given":"Nayara Felicidade Tomaz","family":"Braz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia Pessoa","family":"Rocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9rica Leandro Marciano","family":"Vieira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo Santiago","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana Maria","family":"Kakehasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9621-5422","authenticated-orcid":false,"given":"Antonio Lucio","family":"Teixeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2017.08.3250_bb0005","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/WCO.0b013e32833cc968","article-title":"Autoimmune mediated neuromuscular junction defects","volume":"23","author":"Farrugia","year":"2010","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.jns.2017.08.3250_bb0010","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/mus.20950","article-title":"Lifetime course of myasthenia gravis","volume":"37","author":"Grob","year":"2008","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jns.2017.08.3250_bb0015","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s11910-010-0151-1","article-title":"Treatment of myasthenia gravis","volume":"11","author":"Kumar","year":"2011","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"10.1016\/j.jns.2017.08.3250_bb0020","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/mus.1221","article-title":"Steroid treatment for myasthenia gravis: steroids have an important role","volume":"25","author":"Bedlack","year":"2002","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jns.2017.08.3250_bb0025","doi-asserted-by":"crossref","first-page":"861","DOI":"10.2165\/00002018-200730100-00005","article-title":"Corticosteroid-induced adverse events in adults: frequency, screening and prevention","volume":"30","author":"Fardet","year":"2007","journal-title":"Drug Saf."},{"key":"10.1016\/j.jns.2017.08.3250_bb0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1677\/JOE-07-0606","article-title":"Mechanisms of glucocorticoid-induced myopathy","volume":"197","author":"Schakman","year":"2008","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.jns.2017.08.3250_bb0035","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1007\/s10072-017-2964-z","article-title":"Negative impact of high cumulative glucocorticoids dose in bone metabolism of patients with myasthenia gravis","volume":"38","author":"Braz","year":"2017","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.jns.2017.08.3250_bb0040","first-page":"317","article-title":"Effects of glucocorticoids on energy metabolism and food intake in humans","volume":"271","author":"Tataranni","year":"1996","journal-title":"Am. J. Phys."},{"key":"10.1016\/j.jns.2017.08.3250_bb0045","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1097\/00007611-199909000-00009","article-title":"Prescription medications: a modifiable contributor to obesity","volume":"92","author":"Cheskin","year":"1999","journal-title":"South. Med. J."},{"key":"10.1016\/j.jns.2017.08.3250_bb0050","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1111\/j.1365-2133.2010.09877.x","article-title":"Impact of glucocorticoid-induced adverse events on adherence in patients receiving long-term systemic glucocorticoids therapy","volume":"163","author":"Arena","year":"2010","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.jns.2017.08.3250_bb0055","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.nutres.2013.12.006","article-title":"A systematic review of the effect of oral glucocorticoids on energy intake, appetite, and body weight in humans","volume":"34","author":"Berthon","year":"2014","journal-title":"Nutr. Res."},{"key":"10.1016\/j.jns.2017.08.3250_bb0060","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1093\/rheumatology\/kem062","article-title":"Corticosteroid-induced lipodystrophy is associated with features of the metabolic syndrome","volume":"46","author":"Fardet","year":"2007","journal-title":"Rheumatology"},{"key":"10.1016\/j.jns.2017.08.3250_bb0065","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1080\/03009740600907881","article-title":"Body composition, lipid and lipoprotein levels in childhood-onset systemic lupus erythematosus","volume":"36","author":"Lilleby","year":"2007","journal-title":"Scand. J. Rheumatol."},{"key":"10.1016\/j.jns.2017.08.3250_bb0070","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1093\/rheumatology\/ker004","article-title":"Abnormal body composition phenotypes in Vietnamese women with early rheumatoid arthritis","volume":"50","author":"Dao","year":"2011","journal-title":"Rheumatology"},{"key":"10.1016\/j.jns.2017.08.3250_bb0075","first-page":"237","article-title":"Dual X-ray absorptiometry whole body composition of adipose tissue in rheumatoid arthritis","volume":"53","author":"Popescu","year":"2015","journal-title":"Rom. J. Intern. Med."},{"key":"10.1016\/j.jns.2017.08.3250_bb0080","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.biocel.2011.03.002","article-title":"Molecular mechanisms of human lipodystrophies: from adipocyte lipid droplet to oxidative stress and lipotoxicity","volume":"43","author":"Vigouroux","year":"2011","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.jns.2017.08.3250_bb0085","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1097\/00002030-200307040-00011","article-title":"Serum adipocytokines are related to lipodystrophy and metabolic disorders in HIV-infected men under antiretroviral therapy","volume":"17","author":"Vigouroux","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.jns.2017.08.3250_bb0090","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s00421-008-0904-6","article-title":"Effects of short term corticoid injection on food intake and adipokines in healthy recreationally trained men","volume":"105","author":"Rieth","year":"2009","journal-title":"Eur. J. Appl. Physiol."},{"key":"10.1016\/j.jns.2017.08.3250_bb0095","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1365-2265.2012.04348.x","article-title":"Adipokine profile in glucocorticoid-treated patients: baseline plasma leptin level predicts occurrence of lipodystrophy","volume":"78","author":"Fardet","year":"2013","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.jns.2017.08.3250_bb0100","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.tips.2015.04.014","article-title":"Adipokines in health and disease","volume":"36","author":"Fasshauer","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.jns.2017.08.3250_bb0105","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1007\/s12020-012-9816-7","article-title":"Changes in adipokines but not in body composition after one week of prednisone intake in physically fit women","volume":"43","author":"Jollin","year":"2013","journal-title":"Endocrine"},{"key":"10.1016\/j.jns.2017.08.3250_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis. Recommendations for clinical research standards. Task force of the medical scientific advisory Board of the Myasthenia Gravis Foundation of America","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2017.08.3250_bb0115","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1212\/WNL.0b013e3181dc1b1e","article-title":"The MG composite. A valid and reliable outcome measure for myasthenia gravis","volume":"74","author":"Burns","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2017.08.3250_bb0120","series-title":"Handbooks in health care","article-title":"Contemporary diagnosis and management of obesity and the metabolic syndrome","author":"Bray","year":"2003"},{"key":"10.1016\/j.jns.2017.08.3250_bb0125","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1385\/JCD:6:2:75","article-title":"Clinical applications of body composition measurements using DXA","volume":"6","author":"Albanese","year":"2003","journal-title":"J. Clin. Densitom."},{"issue":"4","key":"10.1016\/j.jns.2017.08.3250_bb0130","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.jocd.2013.08.020","article-title":"The official positions of the International Society for Clinical Densitometry: indications of use and reporting of DXA for body composition","author":"Kendler","year":"2013","journal-title":"J. Clin. Densitom."},{"key":"10.1016\/j.jns.2017.08.3250_bb0135","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/oxfordjournals.aje.a009520","article-title":"Epidemiology of sarcopenia among the elderly in New Mexico","volume":"147","author":"Baumgartner","year":"1998","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.jns.2017.08.3250_bb0140","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1177\/0961203308093552","article-title":"Changes in body composition after glucocorticoid therapy in patients with systemic lupus erythematosus","volume":"17","author":"Mok","year":"2008","journal-title":"Lupus"},{"key":"10.1016\/j.jns.2017.08.3250_bb0145","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1046\/j.1365-2796.2003.01099.x","article-title":"Effects of glucocorticoids on leptin levels and eating behaviour in women","volume":"253","author":"Udd\u00e9n","year":"2003","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.jns.2017.08.3250_bb0150","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/j.1749-6632.2009.05364.x","article-title":"Changes in adiponectin and leptin concentrations during glucocorticoid treatment: a pilot study in patients with polymyalgia rheumatica","volume":"1193","author":"Cimmino","year":"2010","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jns.2017.08.3250_bb0155","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.clim.2009.07.013","article-title":"The role of resistin as a regulator of inflammation: implications for various human pathologies","volume":"133","author":"Filkov\u00e1","year":"2009","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.jns.2017.08.3250_bb0160","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1097\/MEG.0b013e3282f16251","article-title":"Resistin is an inflammatory marker of inflammatory bowel disease in humans","volume":"19","author":"Konrad","year":"2007","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jns.2017.08.3250_bb0165","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1136\/ard.2006.054734","article-title":"Resistin in rheumatoid arthritis synovial tissue, synovial fluid and serum","volume":"66","author":"Senolt","year":"2007","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jns.2017.08.3250_bb0170","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s00296-010-1651-7","article-title":"The serum levels of resistin in ankylosing spondylitis patients: a pilot study","volume":"32","author":"Kocabas","year":"2012","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.jns.2017.08.3250_bb0175","doi-asserted-by":"crossref","first-page":"59","DOI":"10.9758\/cpn.2017.15.1.59","article-title":"The serum levels of Resistin and its relationship with other Proinflammatory cytokines in patients with Alzheimer's disease","volume":"15","author":"Demirci","year":"2017","journal-title":"Clin. Psychopharmacol. Neurosci."},{"key":"10.1016\/j.jns.2017.08.3250_bb0180","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jneuroim.2015.04.004","article-title":"Remarkably increased resistin levels in anti-AChR antibody-positive myasthenia gravis","volume":"283","author":"Zhang","year":"2015","journal-title":"J. Neuroimmunol."},{"issue":"4","key":"10.1016\/j.jns.2017.08.3250_bb0185","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1007\/s00774-013-0511-4","article-title":"Relationships between serum adipocyte hormones (adiponectin, leptin, resistin), bone mineral density and bone metabolic markers in osteoporosis patients","volume":"32","author":"Mohiti-Ardekani","year":"2014","journal-title":"J. Bone Miner. Metab."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X17337462?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X17337462?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,4,4]],"date-time":"2021-04-04T23:27:43Z","timestamp":1617578863000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X17337462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":37,"alternative-id":["S0022510X17337462"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2017.08.3250","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Body composition and adipokines plasma levels in patients with myasthenia gravis treated with high cumulative glucocorticoid dose","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2017.08.3250","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}